Pharmalink AB, a specialty pharma company, recently announced that it has acquired a novel product candidate in development for treating inflammation from Synartro AB. No financial details were disclosed.
The product candidate, which consists of an anti-inflammatory drug conjugated to a biopolymer, was developed using Synartro’s drug delivery technology to create locally acting pharmaceuticals with limited systemic exposure.
Pharmalink intends to develop the product for osteoarthritis, an indication where it has demonstrated promising results in pre-clinical studies. Pharmalink officials said they will apply the formulation and clinical development expertise to advance the candidate product through clinical trials toward market.
Pharmalink’s most advanced product is Nefecon, a new oral, modified-release capsule of the corticosteroid, budesonide, in Phase 2b clinical development for treating patients with IgA nephropathy at risk of developing end-stage renal disease, despite optimized standard-of-care therapy.
READ FULL ARTICLE From www.ulitzer.com